Abstract
BackgroundCD19-directed Chimeric Antigen Receptor T-Cell (CAR-T) therapy has emerged as a promising and novel treatment for relapsed and refractory (r/r) B-cell malignancies. Efforts are directed towards increasing persistence of CAR-T...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have